Medtronic’s Cardiac and Vascular Group is comprised of the Cardiac Rhythm Disease Management, Structural Heart, Endovascular Innovations, Peripheral, Coronary, Renal Denervation, and Physio-Control businesses.

Sales leadership from all of these businesses except Physio-Control is included in the new structure.

Medtronic announced its renewed intent to divest Physio-Control earlier this year.

David Roberts, formerly vice president of Sales for the Cardiac Rhythm Disease Management business, will assume the leadership of the new 2,700 person organization as the national vice president of Cardiac and Vascular Group Sales.

Medtronic has also created a Strategic Account Management team that now reports into the new sales organization.

This team will augment the work of the traditional field representative by focusing exclusively on delivering a cross-business portfolio of products and services to cardiac and vascular-focused hospital administrators.

Medtronic Cardiac and Vascular Group of businesses group president and executive vice president Michael Coyle said their strategy going forward is to leverage Medtronic’s breadth of talent, technologies, products and services across 15 market segments to help hospital administrators address their unmet needs, while maintaining and strengthening their ability to serve clinicians and their patients.